Jump to main content
Jump to site search
PLANNED MAINTENANCE Close the message box

Scheduled maintenance work on Wednesday 27th March 2019 from 11:00 AM to 1:00 PM (GMT).

During this time our website performance may be temporarily affected. We apologise for any inconvenience this might cause and thank you for your patience.

All chapters
Previous chapter Next chapter


Introduction: Biomarkers in Translational and Personalized Medicine

Biomarkers have become a buzzword in the biomedical field and are expected to enable much innovation in the years to come. Their predominant promise resides in two application areas: translational medicine and personalized medicine, whose activities are strongly aimed to improve the management of disease. However, to many the ultimate potential of biomarkers is to change disease management (reactive mode) into health management (preventive mode), in other words keeping healthy people healthy rather than curing diseased patients. Key drivers for such change are molecular biomarkers that allow earlier and more sensitive detection of onset of disease, better molecular classification of disease, improved personalized treatment, and improved monitoring of treatment effects. Many lessons can be learned from pharmaceutical industry where for considerable time biomarkers have been key drivers in drug development projects. This experience in biomarker discovery, validation, development and implementation can potentially be applied to other areas of human medicine including nutriceuticals. We here review the role of biomarkers in pharmaceutical drug development, focussing on translational and personalized medicine, and discuss trends, challenges and opportunities in this field.

Print publication date: 10 Jun 2013
Copyright year: 2013
Print ISBN: 978-1-84973-422-6
PDF eISBN: 978-1-84973-436-3
From the book series:
Drug Discovery